Skip to main content

Commercial genomics


Genomic testing seeks to offer health benefits and can provide other useful services. However, some have raised concerns regarding the potential risks associated with genomic tests being made directly available to consumers, including on the tests’ reliability and accuracy, the support available to consumers for understanding and acting on results, and the impact of these commercial tests on the NHS.

This inquiry builds upon our predecessor Committee’s inquiry, and will make use of evidence submitted to that inquiry. Please only submit new evidence if you want to update or supplement information that the previous Committee had received, or to provide specific evidence on the ‘in-vitro diagnostic medical device’ regulation.

Read the call for evidence for more information about this inquiry.

Upcoming events

View all events

No upcoming events scheduled

Contact us

We can’t usually help you with an individual problem or a specific complaint.

  • Email:
  • Phone: 020 7219 2793 (General enquiries) / 020 7219 3172 (Media enquiries) / 18001 20 7219 2793 (text relay)
  • Address: Science and Technology Committee, House of Commons, London, SW1A 0AA